niftify.in

The Economic Times

Lupin ties up with Scope Opthalmics to market eyecare products in Mexico

Drug maker Lupin has signed a distribution agreement with Ireland-based Scope Ophthalmics to market the Optase range of eye care products in Mexico, aimed at treating conditions like dry eyes, blepharitis, and meibomian gland dysfunction. This deal enhances Lupin’s ophthalmology portfolio while expanding Scope’s presence in Latin America, emphasizing their commitment to improving vision care.

Business Standard

Lupin inks pact with Scope Opthalmics to market eyecare products in Mexico

Drug maker Lupin on Monday said it has inked a distribution pact with Ireland-based Scope Ophthalmics to market a product range, indicated for the treatment of various eye conditions, in Mexico. The company has signed a distribution agreement with Scope for the registration and marketing of Moist Heat Mask, a Tea Tree Oil Eyelid Cleansing Gel and Tea Tree Oil Eyelid Wipes of the Optase range in Mexico. The products are used for eye conditions like dry eyes, blepharitis and meibomian gland dysfunction (MGD). "This expansion of our ophthalmology range reinforces our commitment to enhancing vision care for our patients, improving their quality of life," said Fabrice Egros, President Corporate Development and Growth Markets, Lupin. Through the signature of this collaboration with Lupin, Scope is expanding its footprint in Latin America, Scope CEO Tom Freyne stated. "Mexico is clearly a country of strategic importance for SCOPE where our innovative eyecare products, together with the

Business Standard

Home First Finance Company India Ltd leads losers in 'A' group

Easy Trip Planners Ltd, BF Utilities Ltd, Gland Pharma Ltd and One 97 Communications Ltd are among the other losers in the BSE's 'A' group today, 27 September 2024.

CNBC TV18

Goldman Sachs expects Gland Pharma shares to fall back to their IPO price

Goldman Sachs is anticipating Gland Pharma's profitability to face headwinds. It has highlighted five factors as to why it believes so.

Business Standard

Gland Pharma Ltd gains for third straight session

Gland Pharma Ltd is quoting at Rs 1936.35, up 1.59% on the day as on 12:49 IST on the NSE. The stock is up 14.9% in last one year as compared to a 24.3% jump in NIFTY and a 50.09% jump in the Nifty Pharma index.

The Economic Times

Gland Pharma, Indus Towers lead top 10 companies with highest increase in MF holdings in June quarter

Around 10 companies experienced the largest increase in mutual fund holdings in June 2024

The Economic Times

Gland Pharma, Federal Bank among top 10 companies with highest mutual fund holdings in June quarter

The MF holding stood at Rs 39.59 lakh crore as on June, 2024, an increase of 16.49% over the last quarter. Top 10 companies with the highest MF holding in rupee value terms.​

Business Line

Gland Pharma in talks with a leading biologics player for tie-up

Q1 net down 26 per cent at ₹143.8 crore

Business Line

Movers & Shakers: Stocks that will see action this week

Here is what the charts say about the shares of Gland Pharma, Tata Teleservices (Maharashtra) and Timken India